Literature DB >> 18852340

Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.

William E Klunk.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18852340      PMCID： PMC2637565          DOI： 10.1001/archneur.65.10.1281

Source DB:  PubMed          Journal:  Arch Neurol        ISSN： 0003-9942


× No keyword cloud information.
  22 in total

1.  Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease.

Authors:  M G Spillantini; M Goedert; R Jakes; A Klug
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

2.  Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

Authors:  William E Klunk; Brian J Lopresti; Milos D Ikonomovic; Iliya M Lefterov; Radosveta P Koldamova; Eric E Abrahamson; Manik L Debnath; Daniel P Holt; Guo-feng Huang; Li Shao; Steven T DeKosky; Julie C Price; Chester A Mathis
Journal:  J Neurosci       Date:  2005-11-16       Impact factor: 6.167

3.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.

Authors:  Brian J Lopresti; William E Klunk; Chester A Mathis; Jessica A Hoge; Scott K Ziolko; Xueling Lu; Carolyn C Meltzer; Kurt Schimmel; Nicholas D Tsopelas; Steven T DeKosky; Julie C Price
Journal:  J Nucl Med       Date:  2005-12       Impact factor: 10.057

4.  [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.

Authors:  M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

Review 5.  X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Barbara A Isanski; Manik L Debnath; Chester A Mathis; Steven T Dekosky; William E Klunk
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

6.  PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease.

Authors:  Hiroshi Toyama; Daniel Ye; Masanori Ichise; Jeih-San Liow; Lisheng Cai; David Jacobowitz; John L Musachio; Jinsoo Hong; Mathew Crescenzo; Dnyanesh Tipre; Jian-Qiang Lu; Sami Zoghbi; Douglass C Vines; Jurgen Seidel; Kazuhiro Katada; Michael V Green; Victor W Pike; Robert M Cohen; Robert B Innis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-25       Impact factor: 9.236

7.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

8.  Frequency of stages of Alzheimer-related lesions in different age categories.

Authors:  H Braak; E Braak
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

9.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

10.  Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway.

Authors:  C F Lippa; A M Saunders; T W Smith; J M Swearer; D A Drachman; B Ghetti; L Nee; D Pulaski-Salo; D Dickson; Y Robitaille; C Bergeron; B Crain; M D Benson; M Farlow; B T Hyman; S P George-Hyslop; A D Roses; D A Pollen
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910
View more
  5 in total

Review 1.  Update on amyloid imaging: from healthy aging to Alzheimer's disease.

Authors:  David A Wolk; William Klunk
Journal:  Curr Neurol Neurosci Rep       Date:  2009-09       Impact factor: 5.081

2.  Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.

Authors:  David A Wolk; Igor D Grachev; Chris Buckley; Hala Kazi; M Sean Grady; John Q Trojanowski; Roy H Hamilton; Paul Sherwin; Richard McLain; Steven E Arnold
Journal:  Arch Neurol       Date:  2011-07-11

Review 3.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

4.  Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.

Authors:  Ville Leinonen; Juha O Rinne; Dean F Wong; David A Wolk; John Q Trojanowski; Paul F Sherwin; Adrian Smith; Kerstin Heurling; Mandy Su; Igor D Grachev
Journal:  Acta Neuropathol Commun       Date:  2014-04-22       Impact factor: 7.801

5.  Is there a neuropathology difference between mild cognitive impairment and dementia?

Authors:  Vahram Haroutunian; Lisa B Hoffman; Michal Schnaider Beeri
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.